Profile data is unavailable for this security.
About the company
Ovoca Bio PLC is a clinical-stage biopharmaceutical company focused on women’s health. The Company is developing Orenetide, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). It is focused on women’s health and identifying novel candidates in areas of high unmet medical need. The Company’s lead product, Orenetide (BP-101), is a novel synthetic peptide for the treatment of HSDD and is conveniently administered through a nasal spray. The spray delivers the drug to olfactory and trigeminal nerves in the nasal cavity where the drug accumulates in the olfactory bulb and further in the brain. It is also developing a new treatment for women affected by low libido or sex drive. It owns a patent portfolio that provides effective protection of its technology. The Company operates in Ireland, the United Kingdom and Russia.
- Revenue in GBP (TTM)0.00
- Net income in GBP-1.99m
- Incorporated1985
- Employees5.00
- LocationOvoca Bio PLC17 Pembroke Street, UpperDUBLIN D02 AT22IrelandIRL
- Phone+353 16619819
- Fax+353 16619895
- Websitehttps://ovocabio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Voyager Life PLC | 314.00k | -1.10m | 612.12k | 28.00 | -- | 0.965 | -- | 1.95 | -0.0912 | -0.0912 | 0.0253 | 0.044 | 0.1897 | 1.58 | 3.85 | 11,214.29 | -66.51 | -- | -77.02 | -- | 41.72 | -- | -350.64 | -- | 2.83 | -69.50 | 0.4625 | -- | 59.55 | -- | -38.70 | -- | -- | -- |
| Ovoca Bio PLC | 0.00 | -1.99m | 734.07k | 5.00 | -- | 0.1706 | -- | -- | -0.0244 | -0.0244 | 0.00 | 0.0528 | 0.00 | -- | -- | 0.00 | -27.00 | -17.82 | -32.86 | -19.39 | -- | -- | -- | -- | 4.68 | -48.64 | 0.00 | -- | -- | -- | -6.96 | -- | -- | -- |
| Oxford Cannabinoid Tchnlgs Hldngs PLC | 0.00 | -4.24m | 1.47m | 7.00 | -- | 0.6649 | -- | -- | -0.0044 | -0.0044 | 0.00 | 0.002 | 0.00 | -- | -- | 0.00 | -82.98 | -56.41 | -104.70 | -66.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.16 | -- | -- | -- |
| Nuformix PLC | 0.00 | -436.95k | 1.64m | 2.00 | -- | 0.3549 | -- | -- | -0.0006 | -0.0006 | 0.00 | 0.0056 | 0.00 | -- | -- | -- | -9.50 | -- | -9.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| N4 Pharma PLC | 1.95k | -1.28m | 1.68m | 5.00 | -- | 1.49 | -- | 861.48 | -0.0053 | -0.0053 | 0.00001 | 0.0042 | 0.0011 | -- | 0.009 | 390.00 | -74.20 | -57.05 | -79.41 | -61.13 | -- | -- | -65,475.90 | -309,312.80 | -- | -- | 0.00 | -- | -- | -51.52 | -24.05 | -- | -- | -- |
| ReNeuron Group Plc | 249.00k | -5.07m | 1.93m | 34.00 | -- | 0.7966 | -- | 7.75 | -0.0888 | -0.0888 | 0.0044 | 0.0424 | 0.0246 | -- | 0.6442 | 7,323.53 | -50.10 | -43.12 | -101.09 | -58.50 | -- | -- | -2,037.35 | -714.73 | -- | -- | 0.1247 | -- | 31.51 | 65.26 | 44.18 | -- | -1.31 | -- |
| Hellenic Dynamics PLC | -100.00bn | -100.00bn | 2.17m | 25.00 | -- | 2.53 | -- | -- | -- | -- | -- | 0.006 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.3029 | -- | -- | -- | -- | -- | -- | -- |
| TheraCryf PLC | 396.00k | -3.14m | 2.99m | 9.00 | -- | 0.822 | -- | 7.55 | -0.0114 | -0.0114 | 0.0014 | 0.0085 | 0.0858 | -- | 0.9766 | 44,000.00 | -67.93 | -42.50 | -81.69 | -46.66 | -- | -- | -792.17 | -1,482.46 | -- | -- | 0.00 | -- | -10.41 | -- | 22.41 | -- | -- | -- |
| IXICO PLC | 6.00m | -1.87m | 3.38m | 89.00 | -- | 0.3372 | -- | 0.5641 | -0.0386 | -0.0386 | 0.1241 | 0.2076 | 0.4725 | -- | 3.54 | 67,415.73 | -14.69 | 4.35 | -16.58 | 5.33 | 46.90 | 62.09 | -31.10 | 6.61 | -- | -- | 0.0312 | 0.00 | -22.89 | 4.32 | -214.15 | -- | 92.12 | -- |
| Fusion Antibodies PLC | 1.58m | -2.84m | 3.58m | 50.00 | -- | 1.53 | -- | 2.26 | -0.0861 | -0.0861 | 0.0436 | 0.0245 | 0.5229 | 3.15 | 1.88 | 31,580.00 | -93.94 | -31.29 | -130.56 | -37.72 | -7.41 | 42.58 | -179.67 | -48.25 | 2.32 | -- | 0.0313 | -- | -39.55 | 1.52 | -116.33 | -- | -23.83 | -- |
